Home - Invivoscribe

Cat #: 91210009

LymphoTrack^® Dx IGH FR1 Assay Kit A – MiSeq®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210039

LymphoTrack^® Dx IGH FR1 Assay Panel – MiSeq^®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210129

LymphoTrack^® Dx IGH FR1/2/3 Assay Kit A – MiSeq

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210139

LymphoTrack^® Dx IGH FR1/2/3 Assay Panel – MiSeq

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210089

LymphoTrack^® Dx IGH FR2 Assay Kit A – MiSeq

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210099

LymphoTrack^® Dx IGH FR2 Assay Panel – MiSeq

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210109

LymphoTrack^® Dx IGH FR3 Assay Kit A – MiSeq^®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210119

LymphoTrack^® Dx IGH FR3 Assay Panel – MiSeq^®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210059

LymphoTrack^® Dx IGHV Leader Somatic Hypermutation Assay Kit A – MiSeq®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segments...

View Product

Cat #: 91210069

LymphoTrack^® Dx IGHV Leader Somatic Hypermutation Assay Panel – MiSeq®

The immunoglobulin heavy chain (IGH) gene locus on chromosome 14 (14q32.3) includes 46-52 functional and 30 non-functional variable (VH) gene segmen...

View Product

Cat #: 91220009

LymphoTrack^® Dx IGK Assay Kit A – MiSeq^®

This LymphoTrack® Dx IGK Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis, as it efficie...

View Product

Cat #: 91220019

LymphoTrack^® Dx IGK Assay Panel – MiSeq®

This LymphoTrack® Dx IGK Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis, as it effic...

View Product

Cat #: 92250009

LymphoTrack^® Dx TRB Assay Kit A – MiSeq®

This LymphoTrack TRB Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it efficientl...

View Product

Cat #: 92250019

LymphoTrack^® Dx TRB Assay Panel – MiSeq®

This LymphoTrack TRB Assay – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it efficientl...

View Product

Cat #: 92270019

LymphoTrack^® Dx TRG Assay Kit A – MiSeq^®

This LymphoTrack® TRG Assay Panel – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it effic...

View Product

Cat #: 92270009

LymphoTrack^® Dx TRG Assay Panel – MiSeq^®

This LymphoTrack® TRG Assay Panel – MiSeq® represents a significant improvement over existing clonality assays using fragment analysis as it effic...

View Product

Cat #: 95000009

LymphoTrack^® Dx Software – MiSeq^®

The LymphoTrack® Dx Assays were designed to produce sequencing data that can be analyzed using the LymphoTrack Dx Software – MiSeq® package pr...

View Product

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

PRODUCTS & CLINICAL LAB SERVICES

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

Now Available

Our New Document Search Feature

Need Help Placing an Online Order?

Contact our Customer Service Team

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing